January | February | March | April | May | June | July | August | September | October | November | December |
| ||||||
| Deal title | Principal company | Partner company | Amount awarded ($M) | Date |
| Cystic Fibrosis Foundation to award Aceragen funding to develop ACG-701 for cystic fibrosis-related pulmonary exacerbations | Aceragen Inc. | Cystic Fibrosis Foundation | $3.50 | 1/6/22 |
| Amarna Therapeutics to receive funding from Eurostars to develop screening platform for identification and validation of key self-antigens in a range of NDDs | Amarna Therapeutics BV | European Eurostars Programme | $0.91 | 1/11/22 |
| Vinnova to award Amniotics funding to demonstrate proof of concept of using Amniotics’ stem cell therapy to repair damaged discarded donor lungs for transplantation and for reducing the incidence of unwanted side effects after lung transplantations | Amniotics AB | Vinnova | $0.52 | 1/20/22 |
| Bill & Melinda Gates Foundation to award Aridis Pharmaceuticals funding to evaluate the application of inhaled formulation technology to deliver monoclonal antibodies against influenza and SARS-CoV2 | Aridis Pharmaceuticals Inc. | Bill & Melinda Gates Foundation | Payment unspecified | 1/27/22 |
| DTRA to award Arrevus funding to develop ACG-701 for melioidosis and orphan infectious diseases | Arrevus Inc. | Defense Threat Reduction Agency | $45.00 | 1/5/22 |
| CEPI to award Bionet funding to support variant-proof vaccine program against SARS-CoV-2 variants | Bionet-Asia Co. Ltd. | Coalition for Epidemic Preparedness Innovations | $16.90 | 1/25/22 |
| NIH to award Phase I STTR grant to Biorestorative therapies to evaluate the therapeutic effects on BRTX-100 for lower back pain | Biorestorative Therapies Inc. | National Institutes of Health | $0.26 | 1/4/22 |
| Bay Area Lyme Foundation to award California Center for Functional Medicine funding to evaluate anti-microbial effect of natural products against Lyme disease | California Center for Functional Medicine | Bay Area Lyme Foundation | Payment unspecified | 1/25/22 |
| MJFF to award Cantabio Pharmaceuticals funding to develop Tau protein aggregation inhibitor against Parkinson's disease | Cantabio Pharmaceuticals Inc. | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 1/5/22 |
| Michael J. Fox Foundation for Parkinson’s Research to award Caraway Therapeutics funding to further explore the role of TRPML1 activation in alpha-synuclein processing and clearance | Caraway Therapeutics Inc. | Michael J. Fox Foundation for Parkinson’s Research | Payment unspecified | 1/26/22 |
| Cognition Therapeutics received grant from The Michael J. Fox Foundation for Parkinson's Research for preclinical studies of two sigma-2 receptor modulators in animal models of Parkinson’s disease | Cognition Therapeutics Inc. | Michael J. Fox Foundation for Parkinson's Research | Payment unspecified | 1/4/22 |
| Contrafect received an additional award from the Cystic Fibrosis Foundation to support investigate use of exebacase for treating serious lung infections caused by methicillin-resistant Staphylococcus aureus in people with cystic fibrosis | Contrafect Corp. | Cystic Fibrosis Foundation | Payment unspecified | 1/7/22 |
| Merck to award Elevian with the 2021 Advance Biotech Grant to develop rGDF11 for ischemic and hemorrhagic stroke recovery | Elevian Inc. | Merck KGaA | Payment unspecified | 1/20/22 |
| BMBF to award Evotec funding for the development of EVT-075 against COVID-19 infection | Evotec SE | German Federal Ministry of Education and Research | $8.58 | 1/3/22 |
| Cystic Fibrosis Foundation to award Feldan Therapeutics funding to develop Feldan shuttle technology for cystic fibrosis | Feldan Therapeutics Inc. | The Cystic Fibrosis Foundation | Payment unspecified | 1/18/22 |
| Bay Area Lyme Foundation to award Flightpath Biosciences funding to develop hygromycinA for the treatment of Lyme disease | Flightpath Biosciences | Bay Area Lyme Foundation | Payment unspecified | 1/25/22 |
| National Health and Medical Research Council to award Garvan Institute funding to support the study on bisphosphonates against lung infection | Garvan Institute of Medical Research | National Health and Medical Research Council | Payment unspecified | 1/6/22 |
| CDMRP to award HJF funding to conduct research and evaluate treatments for volumetric muscle loss | Henry M Jackson Foundation for the Advancement of Military Medicine Inc. | Congressional Directed Medical Research Program | $2.00 | 1/20/22 |
| NIST to award funding to IBBR to conduct research and develop therapeutics and vaccines and to improve access to life-saving treatments | Institute for Bioscience and Biotechnology Research | National Institutes of Standards and Technology | $16.80 | 1/13/22 |
| National Institute of General Medical Sciences to award Integrated Micro-Chromatography Systems funding to develop affordable reaction kits to facilitate synthesis of various glycans that can be used for developing therapeutics and diagnostics for neurological diseases, including Huntington's disease, Parkinson's disease and Alzheimer's disease | Integrated Micro-Chromatography Systems Inc. | National Institute of General Medical Sciences | $1.80 | 1/26/22 |
| Kintara received grant from Luxembourg National Research Fund to study VAL-083's mechanism of action research in glioblastoma | Kintara Therapeutics Inc. | Fonds National de la Recherche | Payment unspecified | 1/12/22 |
| The European Union to award HIPRA funding to study SARS-CoV-2-S-RBD vaccine in children, adolescents and immunocompromised patients | Laboratorios Hipra SA | The European Union | $11.18 | 1/20/22 |
| EJP RD to award LQT funding to develop SGK1 inhibition for long QT syndrome | LQT Therapeutics Inc. | The European Union | Payment unspecified | 1/6/22 |
| NHMRC to award Macquarie University funding to conduct a trial on the acceptance and commitment therapy for older people against treatment resistant generalised anxiety disorder | Macquarie University | National Health and Medical Research Council | $0.36 | 1/11/22 |
| BMBF to award Medicines for Malaria Venture funding to conduct research in discovery, translational medicine, and product development against malaria | Medicines for Malaria Venture | German Federal Ministry of Education and Research | Payment unspecified | 1/13/22 |
| NSW Government to award grant to Medlab Clinical to develop a proof-of-concept for NanoCelle against COVID-19 | Medlab Clinical Ltd. | NSW Government | Payment unspecified | 1/14/22 |
| NHLBI to award a STTR grant to Mercator Medsystems for deep vein thrombosis therapy | Mercator Medsystems Inc. | National Heart Lung and Blood Institute | $0.30 | 1/10/22 |
| Thrasher Research Fund to award MCRI funding to study the use of ivermectin against scabies infection in young children | Murdoch Childrens Research Institute | Thrasher Research Fund | $0.26 | 1/17/22 |
| NIA to award Novoron Bioscience funding to investigate therapeutic approach against Alzheimer's disease, CTE and other tauopathies | Novoron Bioscience Inc. | National Institute on Aging | Payment unspecified | 1/28/22 |
| U.S. Biomedical Advanced Research and Development Authority to award Opiant Pharmaceuticals funding for development of OPNT-003 against opioid overdose | Opiant Pharmaceuticals Inc. | U.S. Biomedical Advanced Research and Development Authority | $2.20 | 1/25/22 |
| BMBF to award PATH funding to support the continuity of R&D tools for HIV/AIDS, malaria, tuberculosis and neglected tropical disease | PATH Center for Vaccine Innovation and Access CVIA | German Federal Ministry of Education and Research | Payment unspecified | 1/13/22 |
| NIH to award Penn Medicine funding to conduct Hepatitis C kidney transplantation research | Penn Medicine | National Institutes of Health | $8.00 | 1/4/22 |
| Cystic Fibrosis Foundation to award Peptilogics funding to Investigate PLG-0301 and PLG-0206 for the treatments of lung infections associated with cystic fibrosis | Peptilogics Inc. | The Cystic Fibrosis Foundation | Payment unspecified | 1/5/22 |
| Recro Pharma received a formulation development and cGMP manufacturing contract from an undisclosed department of the U.S. government to support clinical development of a topical dermal drug product for the prevention of skin cancer | Recro Pharma Inc. | U.S. government | $1.50 | 1/26/22 |
| NHMRC to award RMIT University funding to to study the effects of lipid mediators and inflammation against neurodegeneration | RMIT University | National Health and Medical Research Council | $0.50 | 1/11/22 |
| BMBF to award Rnatics funding for the clinical development of RCS-21 against COVID-19 | Rnatics GmbH | Federal Ministry of Education and Research | $6.94 | 1/13/22 |
| BARDA to Spero Therapeutics funding for the development of tebipenem as a treatment for complicated urinary tract infections, including pyelonephritis, in pediatric patients | Spero Therapeutics Inc. | Biomedical Advanced Research and Development Authority | $12.90 | 1/19/22 |
| Innovation Norway to award Targovax funding for development of TG mutant RAS vaccine program and planned clinical trials | Targovax ASA | Innovation Norway | $0.94 | 1/12/22 |
| USAID to award TB Alliance funding to develop new treatments for tuberculosis | TB Alliance | United States Agency for International Development | $30.00 | 1/20/22 |
| NIH to award funding to Feinstein Institutes to conduct studies and identify therapeutic drug targets for hemorrhagic shock | The Feinstein Institute for Medical Research | National Institutes of Health | $2.50 | 1/27/22 |
| MJFF to award Vaxxinity funding for the clinical development of UB-312 against Parkinson’s disease | Vaxxinity Inc. | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 1/10/22 |
| Neuron to award funding to three different researchers from VIB to develop new strategies for prevention, diagnosis or therapy against neurodevelopmental disorders | VIB-KU Leuven Center for Microbiology | ERA-NET Neuron | Payment unspecified | 1/21/22 |
| JDRF to award WCM funding to evaluate an approach to islet cell transplantation, for difficult-to-control type 1 diabetes in mouse models | Weill Cornell Medicine | JDRF | $0.50 | 1/5/22 |
| MJFF to award Yumanity funding to investigate preclinical efficacy and biomarker development for YTX-7739 against Parkinson’s disease | Yumanity Therapeutics Inc. | The Michael J Fox Foundation for Parkinson's Research | $0.50 | 1/11/22 |
| U.S. Department of Defense to award Appili Therapeutics funding for development of ATI-1701 to prevent infection with Francisella tularensis | Appili Therapeutics Inc. | U.S. Department of Defense’s Joint Science and Technology Office of the Defense Threat Reduction Agency | $10.00 | 2/28/22 |
| CDTI to award aptaTargets funding to develop RNA oligonucleotide-based therapies for rare diseases | Aptatargets SL | Centro para el Desarrollo Tecnologico Industrial | $6.18 | 2/3/22 |
| Bpifrance to award Atamyo funding to support clinical trial of ATA-100 against limb-girdle muscular dystrophy | Atamyo Therapeutics SAS | Bpifrance | $2.29 | 2/24/22 |
| Bpifrance to award Cell-Easy funding to optimize the production of MSCs for cell therapies | Cell-Easy | Bpifrance | $8.00 | 2/28/22 |
| Department of Defense to award a SBIR grant to Elektrofi funding to advance formulation technology for antibody development against COVID-19 | Elektrofi | U.S. Department of Defense | Payment unspecified | 2/28/22 |
| U.K. government’s Department of Health and Social Care to award Emergex Vaccines funding to develop a synthetic T-cell vaccine candidate for Chikungunya virus | Emergex Vaccines Holding Ltd. | U.K. government | $0.66 | 2/22/22 |
| CIRM to award Juvena Therapeutics funding to advance the JUV-161 against myotonic dystrophy type 1 | Juvena Therapeutics Inc. | California Institute of Regenerative Medicine | $3.91 | 2/2/22 |
| ERC to award funding to KI to conduct research and identify treatments for different subtypes of depression | Karolinska Institutet | European Research Council | $1.72 | 2/18/22 |
| Oslo Regional Research Fund to award Lytix Biopharma funding to develop LTX-401 against hepatocellular carcinoma | Lytix Biopharma AS | Regionalt Forskningsfond Oslo | $0.33 | 2/15/22 |
| U.S. Department of Defense to award Mediwound funding for the development of Nexobrid as a non-surgical solution for field-care burn treatment | Mediwound Ltd. | U.S. Department of Defense | $1.70 | 2/17/22 |
| BMGF to award NTx funding to develop solutions for mRNA vaccines production and related supply chain issues | Nature's Toolbox Inc. | Bill & Melinda Gates Foundation | Payment unspecified | 2/1/22 |
| U.S. Department of Defense to award Partner Therapeutics funding for the development of Leukine against sulfur mustard gas exposure | Partner Therapeutics Inc. | U.S. Department of Defense | $5.00 | 2/17/22 |
| Department of Defense to award Pimera Therapeutics funding to evaluate PMR-116 against prostate cancer | Pimera Therapeutics Inc. | U.S. Department of Defense | $1.00 | 2/2/22 |
| National Cancer Institute to award Privo Technologies funding to support the first-in-human clinical trial of PRV-211 to treat tumor beds following tumor resection surgery | Privo Technologies Inc. | National Cancer Institute | $2.50 | 2/25/22 |
| National Institute of Allergy and Infectious Diseases to award Siolta Therapeutics funding for the development and optimization of manufacturing approaches for live biotherapeutic products containing strictly anaerobic, non-spore forming bacteria as active pharmaceutical ingredients | Siolta Therapeutics Inc. | National Institute of Allergy and Infectious Diseases | $3.00 | 2/9/22 |
| NIAID to award UCLA funding to study immune responses and related to genetic risk factors against Valley fever | University of California Los Angeles | National Institute of Allergy and Infectious Diseases | $8.40 | 2/15/22 |
| PCF to award funding to University of California to develop PTGES3-AR targets for the treatment of advanced prostate cancer | University of California San Francisco | Prostate Cancer Foundation | Payment unspecified | 2/24/22 |
| NHMRC to award University of New South Wales funding to conduct research and develop treatment programs for HIV and hepatitis C | University of New South Wales | National Health and Medical Research Council | $2.71 | 2/22/22 |
| DeGregorio to award funding to University of Texas Austin to target XRCC1-deficient cells for gastroesophageal cancer | University of Texas Austin | DeGregorio Family Foundation | $0.17 | 2/17/22 |
| Scottish Enterprise to award Valneva funding to support research and development for the manufacture of VLA-2001 for COVID-19 | Valneva SE | Scottish Enterprise | $17.00 | 2/22/22 |
| Scottish Enterprise to award Valneva funding to support development of vaccine manufacturing processes | Valneva SE | Scottish Enterprise | $10.20 | 2/22/22 |
| GHIT to award Astellas Pharma funding to support the development of novel compounds with antimalarial activity | Astellas Pharma Inc | Global Health Innovative Technology Fund | $1.14 | 3/30/22 |
| Bill & Melinda Gates Foundation to award Conagen's grant funding for the development of Conamax platform to produce monoclonal antibodies | Conagen Inc. | Bill & Melinda Gates Foundation | Payment unspecified | 3/29/22 |
| CEPI to award Diosynvax funding to develop a Betacoronavirus vaccine candidate | Diosynvax Ltd. | Coalition for Epidemic Preparedness Innovations | Payment unspecified | 3/8/22 |
| Cystic Fibrosis Foundation to award Eloxx Pharmaceuticals additional funding to support ELX-02 phase II program | Eloxx Pharmaceuticals Inc. | Cystic Fibrosis Foundation | $15.90 | 3/29/22 |
| Cystic Fibrosis Foundation to award Felix Biotechnology funding to develop drugs to manage Pseudomonas aeruginosa lung infections | Felix Biotechnology Inc. | Cystic Fibrosis Foundation | Payment unspecified | 3/4/22 |
| Life Science Innovation to award Fluoguide funding to conduct phase II study for FG-001 against less aggressive brain cancers | Fluoguide A/S | Life Science Innovation North Denmark | $0.15 | 3/18/22 |
| GHIT to award GSK funding to support the preclinical development of monoclonal antibody for Plasmodium falciparum malaria | GlaxosmithKline plc | Global Health Innovative Technology Fund | $4.66 | 3/30/22 |
| JRF to award Helmholtz Zentrum München funding to evaluate alveolar function, regeneration and gene repair in Job syndrome | Helmholtz Zentrum Muenchen | Job Research Foundation | $0.20 | 3/31/22 |
| National Science Foundation to award Iaso Therapeutics funding for development of bacteriophage Q? Mutant as a platform carrier for next-generation vaccines | Iaso Therapeutics Inc. | National Science Foundation | $0.98 | 3/15/22 |
| NIH to award Inomagen Therapeutics funding to continue advancement of gene therapy against atrial fibrillation | Inomagen Therapeutics Inc. (formerly Rhythm Therapeutics) | National Institutes of Health | $1.60 | 3/11/22 |
| CIHR to award INRS funding for the development of glycoconjugate vaccine to treat melioidosis | Institut National De La Recherche Scientifique | Canadian Institutes of Health Research | $0.70 | 3/24/22 |
| UK Biomedical Catalyst to award Invizius grant to conduct clinical studies of H-Guard to reduce the inflammatory effects of hemodialysis | Invizius Ltd. | UK Biomedical Catalyst | $1.35 | 3/30/22 |
| Job Research Foundation to award NIAID funding to develop next-generation CRISPR base editing against Job syndrome | National Institute of Allergy and Infectious Diseases | Job Research Foundation | $0.20 | 3/31/22 |
| Neuromagen Pharma received funding from the Israel Innovation Authority to develop AGS-499 for ALS patients | Neuromagen Pharma Ltd. | Israel Innovation Authority | $0.40 | 3/21/22 |
| NIDA to award Northeastern University funding to develop DNA nanoparticle based gene therapy for opioid use disorder | Northeastern University (China) | National Institute on Drug Abuse | $14.70 | 3/31/22 |
| NIH to award Penn Medicine funding to develop Flash radiation therapy for cancer | Penn Medicine | National Institutes of Health | $12.30 | 3/1/22 |
| Florida High Tech Corridor to award Psilera funding to support a preclinical study of DMT derivatives for mood and addiction disorders | Psilera Inc. | Florida High Tech Corridor Council Inc | $0.13 | 3/8/22 |
| Swedish Research Council to award Quretech Bio funding for development of new antibiotics against infections caused by gram-positive bacteria | Quretech Bio | Swedish Research Council | Payment unspecified | 3/24/22 |
| NIGMS to award SQZ Biotechnologies funding to develop scalable cell replacement therapy against parkinson’s disease | SQZ Biotechnologies Inc. | National Institute of General Medical Sciences | $2.00 | 3/21/22 |
| BARDA to award T2 Biosystems funding to advance technology for detection of bloodstream infections and antimicrobial resistance | T2 Biosystems Inc. | Biomedical Advanced Research and Development Authority | $4.40 | 3/31/22 |
| AMED to award Tagcyx funding to develop TAGX-0003 against Hunner-type interstitial cystitis | Tagcyx Biotechnologies | Japan Agency for Medical Research and Development | Payment unspecified | 3/23/22 |
| Lifearc to award University of Edinburgh funding to discover and develop drugs for treating rare diseases including motor neurone disease, Duchenne muscular dystrophy, spinal fractures and mesothelioma | University of Edinburgh | Lifearc | $0.40 | 3/24/22 |
| NHMRC to award Walter and Eliza funding to develop treatments for blood cancers | Walter and Eliza Hall Institute of Medical Research | National Health and Medical Research Council | $5.00 | 3/31/22 |
| NIAID to award Wockhardt funding to conduct phase I study of WCK-6777 against MDR gram-negative infections | Wockhardt Ltd. | National Institute of Allergy and Infectious Diseases | Payment unspecified | 3/16/22 |
| DOD to award Aclipse Therapeutics funding for the development of M-102 against amyotrophic lateral sclerosis | Aclipse Therapeutics LLC | U.S. Department of Defense Army Medical Research and Development Command | $1.57 | 4/20/22 |
| Michael J. Fox Foundation to award Acurex Therapeutics funding to develop Miro1 biomarker for Parkinson’s disease | Acurex Therapeutics | Michael J. Fox Foundation | Payment unspecified | 4/27/22 |
| JDRF to award Aspect Biosystems funding to develop bioengineered tissue therapeutic for type 1 diabetes | Aspect Biosystems Ltd. | JDRF | Payment unspecified | 4/6/22 |
| NIDDK to award AVM Biotechnology funding to study the potential of AVM-0703 to reverse type 1 diabetes | AVM Biotechnology LLC | National Institute of Diabetes and Digestive Kidney Disease | $1.60 | 4/5/22 |
| Australian Government to award BioCina funding to develop RNA vaccines and therapeutics for diseases including cancer | Biocina Pty Ltd. | Australian Government | $2.22 | 4/5/22 |
| California Institute for Regenerative Medicine to award Bioeclipse Therapeutics funding to support phase I open-label, dose-escalation study of CRX-100 for advanced solid tumors | Bioeclipse Therapeutics Inc. | California Institute for Regenerative Medicine | $7.90 | 4/25/22 |
| NIDA to award Copernicus Therapeutics funding to develop an intranasal gene therapy for treating opioid use disorder | Copernicus Therapeutics Inc. | National Institute on Drug Abuse | $14.70 | 4/4/22 |
| Break Through Cancer to award Dana-Farber Cancer Institute funding to identify and cure cancers, including pancreatic, ovarian cancers and GBM | Dana-Farber Cancer Institute Inc. | Commonwealth Cancer Consortium (dba Break Through Cancer) | $11.00 | 4/19/22 |
| Government of India to fund Epygen Biotech to develop COVID-19 vaccine | Epygen Biotech Pvt. Ltd. | Indian Government Department of Biotechnology | Payment unspecified | 4/13/22 |
| National Institute of Allergy and Infectious Diseases to award Iliad Biotechnologies funding for development of B-Tech vector technology as a prevention of tuberculosis | Iliad Biotechnologies LLC | National Institute of Allergy and Infectious Diseases | Payment unspecified | 4/27/22 |
| National Cancer Institute to award Linnaeus Therapeutics funding for development of LNS-8801 against cancer | Linnaeus Therapeutics Inc. | National Cancer Institute | $4.00 | 4/6/22 |
| MJFF to award Lucy Therapeutics funding for the development of drugs to treat Parkinson’s disease | Lucy Therapeutics Inc. | The Michael J Fox Foundation for Parkinson's Research | $4.90 | 4/11/22 |
| Svenska Sällskapet to award Karolinska Institutet funding to develop anti-senescence immunotherapy for the treatment of pulmonary fibrosis | Medicinsk Forskning | Karolinska Institutet | $0.28 | 4/11/22 |
| Harrington Discovery Institute to award Memorial Sloan funding to block MYC protein production in cancer | Memorial Sloan-Kettering Cancer Center | Harrington Discovery Institute | Payment unspecified | 4/28/22 |
| CEPI to award Migvax funding to develop orally administered subunit vaccine tablet against SARS-CoV-2 variants | Migvax Ltd. | Coalition for Epidemic Preparedness Innovations | $4.30 | 4/8/22 |
| RTW Charitable to award Murdoch Children’s funding to support research of TRAPPC4 gene mutations in children with neurological disease | Murdoch Childrens Research Institute | RTW Investments LP | $0.16 | 4/22/22 |
| CEPI to award NEC Oncoimmunity funding for the development of vaccines for SARS-CoV-2 variants and other betacoronaviruses | NEC Oncoimmunity AS | Coalition for Epidemic Preparedness Innovations | $4.80 | 4/11/22 |
| European Research Council to award two NKI funding to develop a treatment to improve immunotherapy for cancers | Netherlands Cancer Institute | European Research Council | $2.75 | 4/26/22 |
| Michael J. Fox Foundation for Parkinson’s Research to award Neuropore Therapies funding for development of brain-penetrating small-molecule toll-Like receptor 2 antagonist | Neuropore Therapies Inc. | Michael J. Fox Foundation for Parkinson’s Research | $4.80 | 4/20/22 |
| CEPI to award Panacea Biotec funding to develop multi-epitope, nanoparticle-based vaccine candidates against SARS-CoV-2 variants and other Betacoronaviruses | Panacea Biotec Ltd. | Coalition for Epidemic Preparedness Innovations | $12.50 | 4/8/22 |
| UWM Research Foundation to award Pantherics funding to commercialize the developed innovations and to foster the development of startup companies | Pantherics Inc. | University of Wisconsin-Milwaukee | $0.04 | 4/27/22 |
| Medilink to award Phenotypeca ISG funding to develop yeast breeding platform for VHH antibody-based therapeutics | Phenotypeca Ltd. | Medilink East Midlands | Payment unspecified | 4/25/22 |
| CIRM to award Ray Therapeutics funding to develop Ray-001 for the treatment of retinitis pigmentosa and other inherited retinal diseases | Ray Therapeutics Inc. | California Institute of Regenerative Medicine | $4.00 | 4/26/22 |
| Department of Defense to award Spinethera funding to develop SX-600 for the treatment of lumbar radiculopathy | Spinethera Inc. | US Department of Defense | $4.97 | 4/26/22 |
| Harrington Discovery Institute to award Massachusetts General Hospital funding to develop candidates targeting mRNA Methyltransferase in cancer | The General Hospital Corporation | Harrington Discovery Institute | Payment unspecified | 4/28/22 |
| Harrington Discovery Institute to award University of California funding to develop engineered human stem cells for spinal cord injury and bacteriophage therapy for alcoholic hepatitis | University of California | Harrington Discovery Institute | Payment unspecified | 4/28/22 |
| NIAID to award University of California San Diego funding to support the COVAIL phase II clinical trial to evaluate additional COVID-19 booster shots | University of California San Diego | National Institute of Allergy and Infectious Diseases | Payment unspecified | 4/6/22 |
| Harrington Discovery Institute to award University of North Carolina funding to develop Thy-1 mimicry as a therapeutic strategy for pulmonary fibrosis | University of North Carolina | Harrington Discovery Institute | Payment unspecified | 4/28/22 |
| Innosuisse to award University of Zurich funding to support the proof of concept studies of TOP-V122 for pulmonary fibrosis | University of Zurich | Innosuisse Management AG | $0.65 | 4/7/22 |
| CEPI to award Vaxxinity funding to develop UB-612 against COVID-19 | Vaxxinity Inc. | Coalition for Epidemic Preparedness Innovations | $9.25 | 4/8/22 |
| INCA to award Xbiotech funding to conduct a phase I/II/III clinical study of Natrunix in combination with trifluridine/tipiracil for colorectal cancer | Xbiotech Inc. | Institut National du Cancer | Payment unspecified | 4/28/22 |
| NIH to award Aracari Biosciences funding to develop human bone marrow technology for in vivo drug responses | Aracari Biosciences Inc. | National Institutes of Health | Payment unspecified | 5/5/22 |
| The Michael J. Fox Foundation for Parkinson's Research to award Asceneuron funding to accelerate the study of ASN-51 as a new treatment for Parkinson's disease | Asceneuron SA | The Michael J. Fox Foundation for Parkinson's Research | Payment unspecified | 5/4/22 |
| CEPI to award Bharat Biotech funding to support the development of a SARS-CoV-2 vaccine candidate against COVID-19 | Bharat Biotech International Ltd. | Coalition for Epidemic Preparedness Innovations | $19.30 | 5/10/22 |
| BCSC to award Brandon University funding to perform precision genomics research towards breast cancer screening and detection | Brandon University | Breast Cancer Society of Canada | $0.07 | 5/25/22 |
| National Institutes of Health to award Dare Bioscience funding to define end-user preferences among U.S. women to inform the design of long-acting injectable hormonal contraception | Dare Bioscience Inc. | National Institutes of Health | $0.24 | 5/11/22 |
| Innosuisse to award Haya Therapeutics funding to identify and develop fibroblast-specific RNA therapy against squamous cell carcinoma | Haya Therapeutics SA | Innosuisse Management AG | $0.82 | 5/3/22 |
| Innosuisse to award Haya Therapeutics funding to conduct research on antisense oligonucleotide against hypertrophic cardiomyopathy | Haya Therapeutics SA | Innosuisse Management AG | $0.82 | 5/3/22 |
| European Commission to grant Hemispherian funding to establish and optimize synthesis of new drug family to treat glioblastoma multiforme | Hemispherian AS | European Commission | $0.14 | 5/26/22 |
| NIA to award IMM funding to support clinical trials of Needle-free Injection System delivered AV-1959D and duvax for the prevention of AD | Institute for Molecular Medicine | National Institute on Aging | $12.00 | 5/24/22 |
| Eurostars to award Leniobio funding to conduct research and develop glycoprotein production and manufacturing system through HiT-GlyP to discover and develop drugs | Leniobio GmbH | Eurostars | $2.75 | 5/9/22 |
| DoD to award Mimedx funding to evaluate DHACM for treatment of wound and burn care | Mimedx Group Inc. | U.S. Department of Defense | $4.60 | 5/31/22 |
| NIH to award Mount Sinai funding to study the role of the human microbiome in rheumatoid arthritis, systemic lupus, and other autoimmune diseases | Mount Sinai Medical Center, Miami | National Institutes of Health | Payment unspecified | 5/20/22 |
| CEPI to award MCRI funding to conduct a worldwide clinical trial, to improve acceptability and increase access to COVID-19 vaccines | Murdoch Childrens Research Institute | Coalition for Epidemic Preparedness Innovations | $12.30 | 5/4/22 |
| California Institute for Regenerative Medicine to award Neurona Therapeutics funding to support a dose-escalation phase I/II clinical trial of NRTX-1001 for drug-resistant mesial temporal lobe epilepsy | Neurona Therapeutics Inc. | California Institute for Regenerative Medicine | $8.00 | 5/27/22 |
| National Institutes of Health to award Novomedix funding to develop small molecules that protect triple-negative breast cancer patients | Novomedix LLC | National Institutes of Health | $2.00 | 5/26/22 |
| Innovate UK to award NRG Therapeutics funding to develop mPTP small molecule inhibitors for Parkinson's disease and motor neuron disease | NRG Therapeutics Ltd. | Innovate UK | $3.52 | 5/30/22 |
| Bpifrance to award Orphelia Pharma funding to develop a therapy to treat a rare epileptic encephalopathy | Orphelia Pharma SA | Bpifrance | $1.10 | 5/11/22 |
| Innovate UK to award Oxford Vacmedix SBRI funding to research into the development of T-cell based potency assays for cancer vaccines | Oxford Vacmedix | Innovate UK | Payment unspecified | 5/25/22 |
| NIH to receive Postera funding to develop small molecule antiviral therapeutics using artificial intelligence-first approach | Postera | National Institutes of Health | $68.00 | 5/18/22 |
| NIAID to award UCSF QBI to develop therapies against viruses with pandemic potential, including COVID-19 | Quantitative Biosciences Institute | National Institute of Allergy and Infectious Diseases | $67.50 | 5/18/22 |
| Maryland Stem Cell Research Commission to award Renovate Biosciences funding to develop human stem cell-based products | Renovate Biosciences Inc. | Maryland Stem Cell Research Fund | $0.81 | 5/16/22 |
| Maryland Stem Cell Research Commission awarded Roosterbio funding to develop new human stem cell-based products | Roosterbio Inc. | Maryland Stem Cell Research Fund | Payment unspecified | 5/16/22 |
| CEPI to award SVI funding to conduct dose-optimization clinical trial on COVID-19 vaccines | Sabin Vaccine Institute | Coalition for Epidemic Preparedness Innovations | $6.30 | 5/17/22 |
| Melanoma Research Alliance to award The Sheba Fund for Health Service and Research funding to study mRNA-Based Re-Programming of terminally differentiated TILs | Sheba Medical Center | Melanoma Research Alliance | Payment unspecified | 5/19/22 |
| DoD to award Siga funding to develop oral Tpoxx for post exposure prophylaxis indication | Siga Technologies Inc. | U.S. Department of Defense | $7.50 | 5/12/22 |
| NCATS to award Sound Pharmaceuticals funding to develop ebselen (SPI-1005) for hospitalized COVID-19 patients | Sound Pharmaceuticals Inc. | National Center for Advancing Translational Sciences | $1.10 | 5/12/22 |
| NIAID awarded Stanford University School of Medicine funding to develop outpatient antiviral Cocktails against SARS-CoV-2 | Stanford University School of Medicine | National Institute of Allergy and Infectious Diseases | Payment unspecified | 5/19/22 |
| Innovate UK to award Storm Therapeutics funding to develop coronavirus therapy | Storm Therapeutics Ltd. | Innovate UK | Payment unspecified | 5/3/22 |
| BARDA to award Trilink funding to support production capacity for mRNA vaccines and therapeutics | Trilink Biotechnologies | Biomedical Advanced Research and Development Authority | $39.00 | 5/24/22 |
| Università Sapienza di Roma to evaluate radiosensitisation effects of the Evgen Pharma's SFX-01 for the treatment of cancer | Universita degli Studi di Roma La Sapienza | Evgen Pharma plc | Payment unspecified | 5/25/22 |
| MSCRC to award University of Maryland funding to conduct research and develop human stem cell-based therapies | University of Maryland | Maryland Stem Cell Research Fund | Payment unspecified | 5/16/22 |
| Blueprint Neurotherapeutics Network to award University of Miami Miller School of Medicine funding to develop a kinase inhibitor for spinal cord injury | University of Miami Miller School of Medicine | Blueprint Neurotherapeutics Network | $10.00 | 5/17/22 |
| NHMRC to award University of New South Wales grant to conduct MR-CASPER trial in stroke patients | University of New South Wales | National Health and Medical Research Council | $1.54 | 5/24/22 |
| US DoD to award Ventus Therapeutics funding to studt the role of cGAS in lupus treatment | Ventus Therapeutics Inc. | U.S. Department of Defense | Payment unspecified | 5/9/22 |
| PanCAN to award Verastem Oncology funding to evaluate VS-6766 and defactinib for pancreatic ductal adenocarcinoma | Verastem Oncology | Pancreatic Cancer Action Network | $3.80 | 5/18/22 |
| CEPI to award Victoria Biomedical funding to conduct a phase IIb study for COVID-19 vaccine booster regimens in adolescents and adults with HIV | Victoria Biomedical Research Institute | Coalition for Epidemic Preparedness Innovations | $12.50 | 5/11/22 |
| ISED to award Virica funding to manufacture an affordable version of AAV-LPL to treat people with debilitating lipoprotein lipase deficiency | Virica Biotech Inc. | Innovation Science and Economic Development Canada | $0.40 | 5/2/22 |
| NHLBI to award WashUMed funding to investigate the role of macrophages and to develop the immune-based therapeutics for heart failure and to prevent organ rejection following heart transplantation | Washington University School of Medicine in St Louis | National Heart Lung and Blood Institute | $6.00 | 5/2/22 |
| Glyconet and Mitacs to award Zucara Therapeutics funding to support the development of ZT-01 for the treatment of insulin-induced hypoglycemia in patients with type 2 diabetes | Zucara Therapeutics Inc. | Glyconet and Mitacs | Payment unspecified | 5/2/22 |
| National Institute on Drug Abuse to award Achieve Life Sciences grant to evaluate the use of cytisinicline as a treatment to help patients stop using nicotine e-cigarette | Achieve Life Sciences Inc. | National Institute on Drug Abuse | $2.50 | 6/1/22 |
| Australian Government to award funding to Accrue Therapeutics to identify a new class of drugs against acute myeloid leukemia | Acorus Therapeutics Ltd. | Australian Government | Payment unspecified | 6/8/22 |
| European Commission to award funding to Adaptvac led consortium to develop Primvac and Pamvac against placental malaria | Adaptvac | European Commission | $11.00 | 6/13/22 |
| National Institute of Neurological Disorders and Stroke to award Aruna Bio funding to develop AB-126 for traumatic brain injury | Aruna Bio Inc. | National Institute of Neurological Disorders and Stroke | Payment unspecified | 6/1/22 |
| National Cancer Institute to award AVM Biotechnology funding to develop AVM-0703 for leukemia or lymphoma | AVM Biotechnology Inc. | National Cancer Institute | Payment unspecified | 6/14/22 |
| NIA to award Bolden Therapeutics funding to support the development of antisense oligonucleotide candidates against Alzheimer's disease | Bolden Therapeutics | National Institute on Aging | $0.50 | 6/14/22 |
| National Cancer Institute and Cancer Research U.K. to award Boundless Bio funding to understand the role of extrachromosomal DNA in cancer pathogenesis | Boundless Bio | National Cancer Institute and Cancer Research U.K. | $25.00 | 6/20/22 |
| Cystic Fibrosis Foundation to invest in Carbon Biosciences to augment gene therapy approach for cystic fibrosis | Carbon Biosciences Inc. | Cystic Fibrosis Foundation | $6.00 | 6/21/22 |
| Nomi Health to award funding to develop, manufacture and distribute of low-cost insulin for people with diabetes in the U.S. | Civica Inc | Nomi Health | $5.00 | 6/16/22 |
| Flanders Innovation & Entrepreneurship to award Confo Therapeutics funding to develop Confobody drug discovery and development technology in rare diseases | Confo Therapeutics NV | Flanders Innovation & Entrepreneurship | $1.80 | 6/28/22 |
| NCI to award Immunicom funding to conduct clinical trial for Immunopheresis LW-02 molecular subtractive therapy against refractory ER /Her2- breast cancer | Immunicom Inc. | National Cancer Institute | $2.00 | 6/14/22 |
| Itolerance to receive award from JDRF for advanced preclinical development of iTOL-100 and iTOL-101 for the treatment of type 1 diabetes | Itolerance Inc. | Juvenile Diabetes Research Foundation International | $0.85 | 6/28/22 |
| NIH to award STTR grant to Kovina to develop therapeutics against HPV cancers | Kovina Therapeutics Inc. | National Cancer Institute | $2.40 | 6/27/22 |
| Eureka Eurostars to award Lead Pharma and Oxeltix grant to develop a small-molecule therapy to treat diffuse large B-cell lymphoma | Lead Pharma and Oxeltix | Eureka Eurostars | $0.84 | 6/8/22 |
| MND Association to award Lifearc funding to discover therapies against MND | Lifearc | Motor Neurone Disease Association | $1.22 | 6/30/22 |
| US Navy to award Microbion funding for the phase II study of pravibismane against combat Injury-related infections, including diabetic foot ulcer infection | Microbion Corp. | The Government Of The USA As Represented By The Secretary Of The Navy | $2.10 | 6/7/22 |
| European Commission to award Oryzon Genomics funding to develop new treatments against acute myeloid leukemia using iadademstat | Oryzon Genomics SA | European Commission | $2.00 | 6/7/22 |
| Bpifrance to award Osivax funding to develop OVX-836 for the treatment of influenza virus infection | Osivax SAS | Bpifrance | $10.50 | 6/23/22 |
| CRUK to award Rutgers Cancer Institute of New Jersey funding to develop treatments against Cachexia | Rutgers Cancer Institute of New Jersey | Cancer Research UK | $25.00 | 6/16/22 |
| CRUK to award Stanford Medicine funding to conduct research on EcDNA for new treatment discovery | Stanford University School of Medicine | Cancer Research UK | $25.00 | 6/16/22 |
| Gilbert Family Foundation to award Teesside University funding to develop gene therapy for neurofibromatosis type 1 | Teesside University | The Gilbert Family Foundation | $1.00 | 6/10/22 |
| CBCF to award Telethon Kids Institute funding to develop PAT-DX1 and PAT-DX3 programs for glioma | Telethon Kids Institute | Cure Brain Cancer Foundation | Payment unspecified | 6/3/22 |
| Innovate UK to award Theolytics funding to develop therapy for multiple myeloma patients | Theolytics Ltd. | Innovate UK | $1.31 | 6/1/22 |
| Cancer Research UK to award University College London funding to develop treatments for children with solid tumors using engineered T cell therapies | University College London | Cancer Research UK | $25.00 | 6/16/22 |
| Mark Foundation for Cancer Research to award UCL funding to research and develop CAR T-cell therapy for childhood brain tumors and sarcomas | University College London | The Mark Foundation for Cancer Research | $12.00 | 6/16/22 |
| Australian Government to award University of Adelaide funding to identify a therapeutic target for cancer, stroke and heart and metabolic diseases | University of Adelaide | Australian Government | Payment unspecified | 6/8/22 |
| CEPI to award University of Oxford funding to evaluate fractional CoronaVac booster vaccine for COVID-19 infection | University of Oxford | Coalition for Epidemic Preparedness Innovations | $6.40 | 6/8/22 |
| Australian Government to award WEHI funding to develop drugs for lung diseases | Walter and Eliza Hall Institute of Medical Research | Australian Government | Payment unspecified | 6/8/22 |
| Horizon Europe to award Achilles Therapeutics funding to develop smart bioprocessing manufacturing platform for cell therapies | Achilles Therapeutics Ltd. | The European Union | $4.20 | 7/21/22 |
| Biotest to award University of Freiburg funding to support research on Cytotect for CMV infection | Albert-Ludwigs-Universität Freiburg | Biotest AG | $0.05 | 7/25/22 |
| NIHR to award Awakn to conduct phase III trial to evaluate the use of ketamine-assisted therapy for the treatment of AUD | Awakn Life Sciences Inc. | National Institute for Health Research | $0.95 | 7/20/22 |
| Novocure to award Brown University grant for integrated stress response induction by TTFields plus ONC-201 for the treatment of cancer | Brown University | Novocure Ltd. | Payment unspecified | 7/27/22 |
| NIH to award Burke Neurological Institute funding to conduct clinical study for benfotiamine for treatment of Alzheimer’s disease | Burke Neurological Research Institute | National Institutes of Health | $45.00 | 7/7/22 |
| CEPI to award Caltech funding to develop a novel vaccine against COVID-19 | California Institute of Technology | Coalition for Epidemic Preparedness Innovations | $30.00 | 7/5/22 |
| CEPI to award Codiak BioSciences funding to develop vaccines against SARS-CoV-2 and other betacoronaviruses | Codiak Biosciences Inc. | Coalition for Epidemic Preparedness Innovations | $2.50 | 7/5/22 |
| Cystic Fibrosis Foundation to award Destiny Pharma funding to establish the potential of XF-73 drug as a treatment for cystic fibrosis patients infected with methicillin-resistant Staphylococcus aureus | Destiny Pharma plc | Cystic Fibrosis Foundation | Payment unspecified | 7/12/22 |
| EU to award DZNE funding for the development of amyotrophic lateral sclerosis vaccine | Deutsches Zentrum für Neurodegenerative Erkrankungen | The European Union | $2.50 | 7/6/22 |
| NIDA to award Enalare Therapeutics funding to support the development of ENA-001 against respiratory depression | Enalare Therapeutics Inc. | National Institute on Drug Abuse | $2.80 | 7/1/22 |
| MJFF to award RFP grant to Epicentrx's RRx-001 for Parkinson's disease | Epicentrx Inc. | The Michael J Fox Foundation for Parkinson's Research | $0.50 | 7/12/22 |
| CEPI to award Excellgene, Bharat Biotech International and the University of Sydney funding to develop a vaccine candidate against COVID-19 for phase I clinical trials | Excellgene SA; Bharat Biotech International Ltd.; University of Sydney | Coalition for Epidemic Preparedness Innovations | $19.30 | 7/27/22 |
| Brandon Biocatalyst to award George Medicines funding for the development of GMRx-4 against type 2 diabetes | George Medicines Pty Ltd. | Brandon Biocatalyst | $1.04 | 7/20/22 |
| Innosuisse to award Gnubiotics funding to support the development of glycopeptide mediated immunotherapies against Solid Tumors | Gnubiotics Sciences SA | Innosuisse Management AG | $1.44 | 7/6/22 |
| NIAID to award HDT Bio SBIR funding to develop RNA vaccines and therapeutics, enterovirus D68 against neurological condition | HDT Bio Corp. | National Institute of Allergy and Infectious Diseases | $1.50 | 7/20/22 |
| Swedish Research Council to award funding to Karolinska Institutet for the phase III study of rituximab against multiple sclerosis | Karolinska Institutet | Swedish Research Council | Payment unspecified | 7/14/22 |
| NIAID to award Oregon Health & Science University funding to develop and preclinical research of a single-injection gene therapy that codes for the leronlimab protein sequence and will be delivered via an adeno-associated virus vector | Oregon Health & Science University | National Institute of Allergy and Infectious Diseases | $5.00 | 7/12/22 |
| FightMND to award Pasithea funding to develop monoclonal antibody for amyotrophic lateral sclerosis | Pasithea Therapeutics Corp. | FightMND ABN | $0.69 | 7/14/22 |
| North Carolina Biotechnology Center to award Plakous Therapeutics funding to develop and market Protego-PD against necrotizing enterocolitis | Plakous Therapeutics Inc. | North Carolina Biotechnology Center | $0.30 | 7/5/22 |
| Steven & Alexandra Cohen Foundation to award Sage Institute funding to support the development of psychedelic medicine for mental health conditions | Sage Institute for Psychedelic Therapy | Steven & Alexandra Cohen Foundation | $0.25 | 7/26/22 |
| NCATS to award STRM.BIO funding to develop extracellular vesicle technology for non-viral, in vivo delivery of gene therapies against hematologic disease | Strm.Bio Inc. | National Center For Advancing Translational Sciences | $2.10 | 7/26/22 |
| NIDA to award Miami Miller School of Medicine funding to conduct study on effects of cannabis against cardiovascular health in people with HIV | University of Miami Miller School of Medicine | National Institute on Drug Abuse | $2.30 | 7/5/22 |
| Novocure to award University of Nottingham grant to combine Tumor Treating Fields with ion channel blockade | University of Nottingham | Novocure Ltd. | Payment unspecified | 7/27/22 |
| NIHR to award University of Oxford funding to conduct feasibility study for Remsima against post operative delirium/cognitive deficit | University of Oxford | National Institute for Health Research | Payment unspecified | 7/27/22 |
| MJFF to award Zyversa Therapeutics funding for the evaluation of IC-100 effectiveness to block neuroinflammation associated with Parkinson's disease | Zyversa Therapeutics Inc. | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 7/27/22 |
| National Institute of Allergy and Infectious Diseases to award 7 Hills Pharma funding to develop a DNA-based vaccine against Chagas disease | 7 Hills Pharma LLC | National Institute of Allergy and Infectious Diseases | $3.00 | 8/1/22 |
| BARDA to award Arcturus Therapeutics' funding to advance self-amplifying mRNA vaccines against rapid pandemic influenza through phase I studies | Arcturus Therapeutics Inc. | Biomedical Advanced Research and Development Authority | $63.20 | 8/31/22 |
| NIH to award Arkansas Children's Research Institute funding to conduct a study evaluating the course of therapy against candidemia | Arkansas Children's Research Institute | National Institutes of Health | $9.70 | 8/29/22 |
| NCI to award AUM Lifetech funding to advance immunotherapy against lung cancer | AUM Lifetech | National Cancer Institute | $0.40 | 8/17/22 |
| National Cancer Institute to award AVM Biotechnology funding to evaluate the ability of AVM-0703 in combination with standard chemotherapy regimen R-CHOP to reduce R-CHOP cycles in an aggressive, immune-resistant murine B-cell non-Hodgkin lymphoma model | AVM Biotechnology Inc. | National Cancer Institute | Payment unspecified | 8/26/22 |
| Cedars-Sinai and NIAID to develop a technique to identify the role of gut microbes against inflammatory diseases | Cedars-Sinai Medical Center | National Institute of Allergy and Infectious Diseases | Payment unspecified | 8/17/22 |
| Hong Kong government to award Celleron Therapeutics funding to support the phase II clinical trial of zabadinostat in liver cancer | Celleron Therapeutics Ltd. | Hong Kong Government | Payment unspecified | 8/15/22 |
| U.S. Department of Defense to award Codagenix funding to develop Codavax-denv for dengue | Codagenix Inc. | U.S. Department of Defense | $4.40 | 8/18/22 |
| National Institute on Drug Abuse to award Columbia University funding for clinical testing of BXCL-501 (sublingual dexmedetomidine) for treating opioid withdrawal | Columbia University | National Institute on Drug Abuse | $7.80 | 8/1/22 |
| Bill & Melinda Gates Foundation to award Eleven Therapeutics funding for development of prophylactics against endemic and pandemic-poised respiratory viruses | Eleven Therapeutics Ltd. | Bill & Melinda Gates Foundation | $9.00 | 8/2/22 |
| Cancer Prevention & Research Institute of Texas to award Emtora Biosciences funding to develop Erapa for treatment of familial adenomatous polyposis | Emtora Biosciences | Cancer Prevention & Research Institute of Texas | $16.90 | 8/22/22 |
| KHIDI to award Eyegene funding to develop gene-recombinant vaccine against Japanese encephalitis | Eyegene Inc. | Korea Health Industry Development Institute | $0.11 | 8/9/22 |
| US Army Medical to award HDT Bio funding to develop HDT-201 for the treatment of viral infections | HDT Bio Corp. | US Army Medical Research Acquisition Activity | $1.80 | 8/8/22 |
| NIAID to award Helocyte funding to support phase II COLT study of Triplex vaccine against Cytomegalovirus infection | Helocyte Inc. | National Institute of Allergy and Infectious Diseases | $20.00 | 8/11/22 |
| KDDF to award Ilias Biologics funding to research and develop CARD9/TRIM62 inhibitors for inflammatory bowel disease | Ilias Biologics Inc. | Korea Drug Development Fund | $0.92 | 8/11/22 |
| UK Biomedical Catalyst award Infex funding to develop SARS-CoV-2 inhibitors for the treatment of COVID-19 infection | Infex Therapeutics Ltd. | UK Biomedical Catalyst | $1.21 | 8/8/22 |
| NIH to award Medipharm funding to conduct clinical study to evaluate efficacy of THC and CBD against dementia and agitation | Medipharm Labs Inc. | National Institutes of Health | Payment unspecified | 8/9/22 |
| Victorian government to award Monash University funding to develop mRNA vaccines and therapeutics for unidentified diseases | Monash University | Victorian State Government | $5.40 | 8/9/22 |
| National Institute on Aging to award Oligomerix funding to support clinical development of OLX-07010 | Oligomerix Inc. | National Institute on Aging | $3.35 | 8/9/22 |
| BARDA to award Opiant Pharmaceuticals funding to develop OPNT-003 for the treatment of opioid overdose | Opiant Pharmaceuticals Inc. | U.S. Biomedical Advanced Research and Development | $2.10 | 8/9/22 |
| Cancer Prevention and Research Institute of Texas to award Panther Therapeutics funding to develop PTM-01 for non-metastatic pancreatic cancer | Panther Therapeutics Inc. | Cancer Prevention & Research Institute of Texas | $14.20 | 8/22/22 |
| NCCN to award Pfizer and Myovant Sciences funding for research projects seeking to improve cardiovascular management of patients with prostate cancer being treated with androgen-deprivation therapy | Pfizer Inc. and Myovant Sciences Ltd. | National Comprehensive Cancer Network | $1.50 | 8/30/22 |
| CPRIT to award Plus Therapeutics funding to develop Rhenium-186 NanoLiposome for leptomeningeal metastases | Plus Therapeutics Inc. | Cancer Prevention and Research Institute of Texas | $17.60 | 8/17/22 |
| NIH to award Prolocor funding to support the analytical validation of platelet expression of Fc?RIIa for cardiovascular disease | Prolocor Inc. | National Institutes of Health | $2.00 | 8/16/22 |
| NIIMBL to award Rutgers funding to support the production of glycosylated monoclonal antibodies | Rutgers University | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 8/9/22 |
| The Michael J. Fox Foundation for Parkinson's Research to award Seelos Therapeutics funding to develop SLS-004 for Parkinson's disease | Seelos Therapeutics Inc. | The Michael J. Fox Foundation for Parkinson's Research | Payment unspecified | 8/24/22 |
| Symbio to supply BCV IV to NINDS to conduct preclinical studies against Epstein Barr virus infections | Symbio Pharmaceuticals Ltd. | National Institute of Neurological Disorders and Stroke | Payment unspecified | 8/9/22 |
| Lupus Research Alliance to award Feinstein Institutes for Medical Research funding to conduct study on remission and future therapies for systemic lupus erythematosus | The Feinstein Institute for Medical Research | Lupus Research Alliance Inc. | $3.00 | 8/24/22 |
| Biocurate to award Burnet Institute proof of concept funding to develop HIV antivirals | The Macfarlane Burnet Institute for Medical Research and Public Health | Biocurate Pty Ltd. | Payment unspecified | 8/4/22 |
| NIIMBL to award NIPTE funding to improve chemical sensitivity for bioreactor monitoring | The National Institute for Pharmaceutical Technology and Education | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 8/9/22 |
| NIDA to award Tonix Pharmaceuticals funding to develop TNX-1300 against cocaine intoxication | Tonix Pharmaceuticals Holding Corp. | National Institute on Drug Abuse | Payment unspecified | 8/2/22 |
| LRA to award UNAM funding to develop therapeutics for systemic lupus erythematosus | Universidad Nacional Autonoma De Mexico | Lupus Research Alliance | $3.00 | 8/24/22 |
| LRA to award UCL funding to develop therapeutics for systemic lupus erythematosus | University College London | Lupus Research Alliance | $3.00 | 8/24/22 |
| NIIMBL to award University of Delaware funding to support the production of cell therapies | University of Delaware | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 8/9/22 |
| LRA to award UNAM funding to develop therapeutics for systemic lupus erythematosus | University of Munster | Lupus Research Alliance | $3.00 | 8/24/22 |
| National Institute of Neurological Disorders and Stroke to award Alume Biosciences funding for commercialization of ALM-488 in surgery | Alume Biosciences Inc. | National Institute of Neurological Disorders and Stroke | $3.40 | 9/12/22 |
| NIAID to award AN2 Therapeutics funding to develop epetraborole for acute systemic melioidosis | An2 Therapeutics Inc. | National Institute of Allergy and Infectious Diseases | $17.80 | 9/29/22 |
| NIH to award Aqualung therapeutics funding to develop ALT-100 against pulmonary arterial hypertension and inflammatory bowel disease | Aqualung Therapeutics Corp. | National Institutes of Health | $4.80 | 9/21/22 |
| MRFF to award Burnet Institute funding to support COVID-19 vaccine responses study | Austin Research Institute | Medical Research Future Fund | $6.30 | 9/6/22 |
| Brandon Biocatalyst to award Azura funding to evaluate AZR-MD-001 with contact lens discomfort | Azura Ophthalmics Ltd. | Brandon Biocatalyst | Payment unspecified | 9/7/22 |
| National Institute on Aging to award Bolden Therapeutics funding for the development of oligonucleotides to promote neurogenesis | Bolden Therapeutics Inc. | National Institute on Aging | $0.40 | 9/19/22 |
| ALS Association to award BWH grant to study the utility of an intranasal anti-CD3 monoclonal antibody in an animal model of ALS | Brigham & Women's Hospital Inc | ALS Association | Payment unspecified | 9/15/22 |
| NIH to award CCHMC to study the efficacy of fluoxetine in restoring the loss of CHD8 gene function for the treatment of autism | Cincinnati Children's Hospital Medical Center | National Institutes of Health | Payment unspecified | 9/23/22 |
| NIA to award Cognition Therapeutics' funding to conduct SEQUEL Study of CT-1812 for Alzheimer’s disease | Cognition Therapeutics Inc. | National Institute on Aging | $2.14 | 9/27/22 |
| Gastro-Intestinal Research Foundation to award Elicio Therapeutics funding to develop ELI-007 and ELI-008 for cancer | Elicio Therapeutics Inc. | Gastro-Intestinal Research Foundation | $2.80 | 9/20/22 |
| BARDA to award Enalare Therapeutics funding to develop an intramuscular formulation of ENA-001 as a treatment for drug overdose and a medical countermeasure for mass casualty events | Enalare Therapeutics Inc. | Biomedical Advanced Research and Development Authority | $50.30 | 9/28/22 |
| NIAAA to award Epivario funding to support the development of ACSS-2 small molecule inhibitors against alcohol use disorder | Epivario Inc. | National Institute on Alcohol Abuse and Alcoholism | $0.26 | 9/13/22 |
| FDA's Office of Center for Drug Evaluation and Research to award Epivax funding to validate a method for measuring immunogenicity risk of host cell proteins | Epivax Inc. | FDA's Office of Center for Drug Evaluation and Research | $2.00 | 9/12/22 |
| National Institutes of Health to grant for the development of gonorrhea lead vaccine candidate | Evaxion Biotech ApS | National Institutes of Health | Payment unspecified | 9/6/22 |
| CIRM to award Excision funding to support the clinical development of EBT-101 against HIV-1 | Excision Biotherapeutics Inc. | California Institute of Regenerative Medicine | $6.85 | 9/29/22 |
| National Institute of Allergy and Infectious Diseases to award Forge Therapeutics funding to develop FG-LpxC UTI for the treatment of urinary tract infections caused by multidrug-resistant gram-negative bacteria | Forge Therapeutics Inc. | National Institute of Allergy and Infectious Diseases | $17.20 | 9/29/22 |
| MRFF to award Garvan Institute of Medical Research funding for genetic resource database to identify disease-causing genetic changes | Garvan Institute of Medical Research | Australian Government | $10.00 | 9/26/22 |
| Lungevity to award Georgetown University funding to conduct phase II study of atezolizumab and tiragolumab regimens in combination with bevacizumab for EGFR-positive non-small cell lung cancer | Georgetown University | Lungevity Foundation | Payment unspecified | 9/27/22 |
| DOD to award Gigagen funding to discover human polyclonal antibody drugs for toxins and pathogens | Gigagen Inc. | U.S. Department of Defense | Payment unspecified | 9/15/22 |
| National Heart, Lung and Blood Institute to award I-Cordis funding to further develop immune-modulatory treatment for heart failure with preserved ejection fraction | I-Cordis LLC | National Heart, Lung and Blood Institute | $1.55 | 9/2/22 |
| CPRIT to award ImmuneSensor funding to support the clinical development of IMSA-101 against metastatic solid tumor malignancies | Immunesensor Therapeutics Inc. | Cancer Prevention and Research Institute of Texas | $16.10 | 9/20/22 |
| Polish government to award Immutep’s phase II study of efti for select soft tissue sarcoma | Immutep SAS | Polish Government | $1.51 | 9/6/22 |
| NIH to award Infextious Therapeutic funding to develop cyclic amphiphilic peptides against microbial infections | Infextious Therapeutics Inc. | National Institutes of Health | Payment unspecified | 9/8/22 |
| NINDS to award Infixion Phase I SBIR funding for drug discovery efforts against neurofibromatosis type 1 | Infixion Bioscience Inc. | National Institute of Neurological Disorders and Stroke | Payment unspecified | 9/20/22 |
| Lungevity to award JHUSOM funding to conduct phase II study of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer | Johns Hopkins University School of Medicine | Lungevity Foundation | Payment unspecified | 9/27/22 |
| NIAID to award Kovina Therapeutics funding to advance the treatments for Human Papillomavirus Premalignant Infection | Kovina Therapeutics Inc. | National Institute of Allergy and Infectious Diseases | $0.30 | 9/12/22 |
| Bavarian Research Foundation to award LMU funding to develop anti-CD40 antibody for organ rejection | Ludwig-Maximilians University of Munich | Bavarian Research Foundation | Payment unspecified | 9/28/22 |
| US FDA to award Marker Therapeutics funding to support the phase II trial of MT-401 against post-transplant acute myeloid leukemia | Marker Therapeutics Inc. | Food and Drug Administration | $2.00 | 9/13/22 |
| Lungevity to award MSKCC funding to identify therapeutics targeting BRAF fusion lung cancer | Memorial Sloan Kettering Cancer Center | Lungevity Foundation | Payment unspecified | 9/27/22 |
| NIAID to award Moleculin funding for the preclinical study of WP-1096 against Hemorrhagic fever arenaviruses | Moleculin Biotech Inc. | National Institute of Allergy and Infectious Diseases | Payment unspecified | 9/27/22 |
| SOLVE FSHD to award n-Lorem funding to support drug research and development for facioscapulohumeral muscular dystrophy-2 patients | n-Lorem Foundation | Solve FSHD | $1.00 | 9/13/22 |
| Bill & Melinda to award Nuvisan funding to discover and develop non-hormonal contraceptive medicines | Nuvisan | Bill & Melinda Gates Foundation | $9.60 | 9/20/22 |
| Brandon Biocatalyst to award Occurx funding to accelerate the clinical development of oral OCX-063 for CKD, inflammation and fibrosis | Occurx | Brandon Biocatalyst | $16.00 | 9/5/22 |
| Sweden's Innovation Agency to award Oncopeptides funding to develop synthetic small polypeptide against multiple myeloma | Oncopeptides AB | Vinnova | $0.46 | 9/7/22 |
| Team Arnav Foundation to award OS Therapies' funding to conduct a phase IIb AOST-2121 clinical study of OST-HER2 in Osteosarcoma | OS Therapies LLC | Team Arnav Foundation | Payment unspecified | 9/22/22 |
| Parkinson’s UK to award Pharmaxis to conduct phase II study of PXS?4728 for the treatment of Parkinson’s disease | Pharmaxis Ltd. | Parkinson's UK | $3.36 | 9/1/22 |
| Pinetree Therapeutics and professors Jason Evans and Nurit Haspel at the University of Massachusetts Boston received funding from the Massachusetts Life Sciences Center’s Bits and Bytes program to develop next-generation biotherapeutics | Pinetree Therapeutics Inc. | Massachusetts Life Sciences Center’s Bits and Bytes program | $2.50 | 9/28/22 |
| BARDA to award Sabin Vaccine Institute funding to develop vaccine against Marburg virus disease | Sabin Vaccine Institute | Biomedical Advanced Research and Development Authority | $21.80 | 9/14/22 |
| NINDS to award Seelos Therapeutics funding to conduct clinical study evaluating SLS-005 in an expanded access program against ALS | Seelos Therapeutics Inc. | National Institute of Neurological Disorders and Stroke | Payment unspecified | 9/30/22 |
| European Commission to award Siga funding to supply oral Tpoxx against small pox infection | Siga Technologies Inc. | European Commission | Payment unspecified | 9/26/22 |
| Michael J Fox to award Sinfonia funding to develop combinatorial gene therapy for Parkinson’s disease | Sinfonia Biotherapeutics AB | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 9/8/22 |
| USFDA to award Soligenix funding to support the phase III expanded study of HyBryte for cutaneous T-Cell Lymphoma | Soligenix Inc. | Food and Drug Administration | $2.60 | 9/6/22 |
| National Institute of Neurological Disorders and Stroke to award South Rampart Pharma funding to develop SRP-001 for reduced liver toxicity | South Rampart Pharma LLC | National Institute of Neurological Disorders and Stroke | $1.90 | 9/22/22 |
| NIDDK to award TGEN funding to examine and characterize the cargo of circulating EVs in NAFLD | Translational Genomics Research Institute | National Institute of Diabetes and Digestive and Kidney Diseases | $3.90 | 9/29/22 |
| CDC to award UCLA funding to study the effectiveness of COVID-19 vaccines and the long-term impact of infection | University of California Los Angeles | Centers for Disease Control and Prevention | $13.60 | 9/13/22 |
| NIDCD to award University of Miami Miller funding to develop gene therapy against hearing loss in Usher syndrome | University of Miami Miller School of Medicine | National Institute on Deafness and Other Communication Disorders | $3.50 | 9/22/22 |
| NIH to award Sylvester Cancer Center to study the role of AURKA and CDK1 role in H. pylori associated gastric cancers | University of Miami Sylvester Comprehensive Cancer Center | National Institutes of Health | $4.60 | 9/1/22 |
| MRFF to award WEHI funding to support genomics project for precision medicine and personalized cancer treatment | Walter and Eliza Hall Institute of Medical Research | Medical Research Future Fund | $2.50 | 9/26/22 |
| Gates Foundation grants fund to Adapsyn Bioscience to discover new therapeutics targeting tuberculosis | Adapsyn Bioscience Inc. | Bill & Melinda Gates Foundation | Payment unspecified | 10/18/22 |
| U.S. Defense Health Agency to award Adaptive Phage Therapeutics funding to develop adaptive bacteriophage therapy in treatment of diabetic foot osteomyelitis | Adaptive Phage Therapeutics Inc. | U.S. Defense Health Agency | $5.00 | 10/4/22 |
| BARDA to award Allosource funding to supply Pureskin allograft for treatment of mass casualty skin burns | Allosource | Biomedical Advanced Research and Development Authority | Payment unspecified | 10/12/22 |
| National Institute of Diabetes and Digestive and Kidney Diseases to award Amidebio funding to develop long-acting soluble stable glucagon analog for hyperinsulinism | Amidebio LLC | National Institute of Diabetes and Digestive and Kidney Diseases | $2.70 | 10/4/22 |
| European Innovation Council to award Arthex Biotech funding to develop disease-modifying treatments for patients with myotonic dystrophy type 1 | Arthex Biotech SL | European Innovation Council | $14.00 | 10/25/22 |
| Mary Kay Ash Foundation to award BSWDF funding to support breast cancer research | Baylor Scott & White Dallas Foundation | Mary Kay Ash Foundation | Payment unspecified | 10/21/22 |
| BARDA to award Biolink Life Sciences funding to develop repurposed ramatroban against COVID-19 pneumonia | Biolink Life Sciences Inc. | Biomedical Advanced Research and Development Authority | $0.75 | 10/5/22 |
| NIGMS to award Cytosorbents funding to test polymers for cytokines and LPS endotoxin removal in septic porcine plasma | Cytosorbents Corp. | National Institute of General Medical Sciences | $0.28 | 10/31/22 |
| Eurostars to award DC4U LUMC funding to develop treatment for Type I diabetes | DC4U BV | Eurostars | $1.69 | 10/25/22 |
| EIC to award Immunethep funding to conduct human clinical trial of PNV vaccine against bacterial infections | Immunethep SA | European Commission | $2.45 | 10/18/22 |
| NIAID to award Intravacc funding to develop NGoXIM against Neisseria gonorrhoeae infection | Intravacc BV | National Institute of Allergy and Infectious Diseases | $14.60 | 10/5/22 |
| CEPI to award Intravacc funding to develop Betacoronavirus vaccine | Intravacc BV | Coalition for Epidemic Preparedness Innovations | $4.80 | 10/6/22 |
| Leo foundation to award KI to discover and develop therapies against psoriasis and psoriasis arthritis | Karolinska Institutet | LEO Pharma A/S | $0.48 | 10/31/22 |
| Innovate UK to award Labgenius funding to expand drug discovery platform, EVA to optimize antibody-based immune cell engager molecules | Labgenius Ltd. | Innovate UK | $27.59 | 10/7/22 |
| CIRM to award Lutris Pharma funding to develop LUT-017 against wound healing | Lutris Pharma Ltd. | California Institute of Regenerative Medicine | $5.00 | 10/24/22 |
| Duchenne UK to award Metriopharm funding to evaluate the efficacy of MP-1032 for the treatment of Duchenne muscular dystrophy | Metriopharm AG | Duchenne UK | $0.12 | 10/12/22 |
| National Cancer Institute to award Modifi Biosciences funding to develop precision oncology platform | Modifi Biosciences Inc. | National Cancer Institute | $2.40 | 10/25/22 |
| MTPConnect to award Monash funding to advance research for the development a drug for type 1 diabetes | Monash University | MTPConnect | $0.75 | 10/21/22 |
| Parkinson’s Foundation to award Mount Sinai funding to conduct profiling and identify neuroprotective strategies to treat PD | Mount Sinai Medical Center, Miami | Parkinson’s Foundation | $2.00 | 10/3/22 |
| MJFF to award Muna funding to do research and develop Kv1.3 blockers for Parkinson's disease | Muna Therapeutics ApS | The Michael J Fox Foundation for Parkinson's Research | $4.90 | 10/11/22 |
| U.S. Department of Defense to award Nervgen Pharma funding to develop NVG-291-R for peripheral nerve injury | Nervgen Pharma Corp. | U.S. Department of Defense | $1.50 | 10/12/22 |
| National Institutes of Health to award Oligomerix funding to support clinical development of OLX-07010 for Alzheimer’s disease | Oligomerix Inc. | National Institutes of Health | $2.50 | 10/5/22 |
| BARDA to award Oncotelic Therapeutics funding to develop OT-101 against COVID-19 | Oncotelic Inc. | Biomedical Advanced Research and Development Authority | Payment unspecified | 10/12/22 |
| NIDA to award Phoenix PharmaLabs funding to study the PPL-138 for treatment of cocaine use disorder | Phoenix Pharmalabs Inc. | National Institute on Drug Abuse | $8.70 | 10/6/22 |
| National Institute of Aging to award Praetego funding to develop PTG-630 against Alzheimer’s Disease | Praetego Inc. | National Institute of Aging | $2.50 | 10/4/22 |
| NCI to award grant to Providence Cancer Institute to conduct phase II study of combination of pembrolizumab with GB-1211 for metastatic melanoma and head and neck squamous cell carcinoma | Providence Cancer Center | National Cancer Institute | Payment unspecified | 10/19/22 |
| CSL to award QIMR funding to investigate the function of T cells in malarial infection and vaccination | Queensland Institute of Medical Research | CSL Ltd. | $1.25 | 10/14/22 |
| Australian Research Council to award Queensland University of Technology funding to develop pesticide against fall armyworm | Queensland University of Technology | Australian Research Council | $0.25 | 10/5/22 |
| ESD to award Renbio funding to to support the development and to deliver next-generation antibody and protein medicines against infectious diseases | Renbio Inc. | The Empire State Development Corporation | $2.00 | 10/12/22 |
| National Institutes of Health to award Sapience Therapeutics funding to conduct nonclinical studies to identify predictive and pharmacodynamic biomarkers of activity of ST-101 in patient-derived breast cancer models | Sapience Therapeutics Inc. | National Institutes of Health | Payment unspecified | 10/5/22 |
| BARDA to award Seqirus contract to manufacture a vaccine against avian flu | Seqirus Inc. | Biomedical Advanced Research and Development Authority | $30.10 | 10/12/22 |
| CEPI to award SK Bioscience funding to develop mRNA vaccines for infectious diseases | SK Bioscience Co. Ltd. | Coalition for Epidemic Preparedness Innovations | $140.00 | 10/25/22 |
| National Cancer Institute to award Synergys Biotherapeutics funding to develop SYN-001 for triple-negative breast cancer | Synergys Biotherapeutics Inc. | National Cancer Institute | Payment unspecified | 10/11/22 |
| UKRI to award Pirbright Institute funding to develop diagnostic tests, therapies and evaluate vaccine effectiveness against monkeypox virus | The Pirbright Institute | United Kingdom Research & Innovation | $2.25 | 10/20/22 |
| Curebound to award Salk funding to discover targets and therapeutics for neuroblastoma, pancreatic and breast cancers | The Salk Institute for Biological Studies | Curebound | $3.00 | 10/19/22 |
| NEI to award Trethera a Fast-Track STTR grant to develop TRE-515 against optic neuritis | Trethera Corp. | National Eye Institute | $1.60 | 10/19/22 |
| U.S. Department of Defense to award Treventis funding to develop a small molecule anti-tau misfolding drug against neurodegenerative diseases | Treventis Corp. | U.S. Department of Defense | $2.98 | 10/18/22 |
| U.S. FDA Office of Orphan Products to award Tvax Biomedical funding for its planned glioblastoma study | Tvax Biomedical Inc. | U.S. FDA Office of Orphan Products | $2.00 | 10/18/22 |
| University of British Columbia to receive funding from Mitacs to develop next generation COVID-19 vaccine technologies | University of British Columbia | Mitacs Inc. | Payment unspecified | 10/11/22 |
| NCI to award UC San Diego Center funding to support the preclinical study of MIE-101 against cancer | University of California San Diego Jacobs School of Engineering | National Cancer Institute | $4.30 | 10/31/22 |
| NIAID to award UCSDSM funding to conduct phage trial to treat cystic fibrosis patients with MDR bacterial infections including P. aeruginosa | University of California San Diego School of Medicine | National Institute of Allergy and Infectious Diseases | Payment unspecified | 10/11/22 |
| American Lung Association to award University of California funding to conduct study evaluating cadherin-11 and develop therapies against asthma | University of California San Francisco | American Lung Association | Payment unspecified | 10/12/22 |
| Department of Defense to award University of North Carolina funding to conduct OASIS Trial of ACER-801 (Osanetant) for post-traumatic stress disorder | University of North Carolina | Department of Defense | $3.00 | 10/6/22 |
| Department of Defense to award UNC funding to support OASIS Trial of ACER-801 for PTSD | University of North Carolina Greensboro | Canadian Department of National Defence | $3.00 | 10/6/22 |
| NIH to award Perelman School of Medicine funding to study blood thinners apixaban versus rivaroxaban in heart disease patients | University of Pennsylvania School of Medicine | National Institutes of Health | Payment unspecified | 10/17/22 |
| Chuck Noll Foundation to award Pitt funding to evalaute Glyburide for brain injury and impact of obesity on blood-based biomarkers | University of Pittsburgh | Chuck Noll Foundation | $0.25 | 10/6/22 |
| CEPI to award University of Saskatchewan funding to develop a vaccine based on VIDO's protein subunit technology against COVID-19 variants | University of Saskatchewan | Coalition for Epidemic Preparedness Innovations | $5.00 | 10/6/22 |
| U.S. Defense Advanced Research Projects Agency to award Vanderbilt University Medical Center funding to develop DNA Therapeutics MYO technology platform for infectious disease | Vanderbilt University Medical Center | U.S. Defense Advanced Research Projects Agency | $4.60 | 10/12/22 |
| Bpifrance to award Vect-Horus funding for the development of VECTrans platform for ophthalmology | Vect-Horus SAS | Bpifrance | $0.20 | 10/7/22 |
| BARDA to award funding to develop Venatorx's VNRX-5133 against melioidosis and multi-drug resistant infections | Venatorx Pharmaceuticals Inc. | Biomedical Advanced Research and Development Authority | $318.00 | 10/3/22 |
| National Institutes of Health to award Viewpoint Molecular Targeting funding to assess image-guided dosimetry-based alpha particle therapy for neuroblastoma | Viewpoint Molecular Targeting Inc. | National Institutes of Health | $2.00 | 10/12/22 |
| National Institutes of Health to award Viewpoint Molecular Targeting funding to combine receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma | Viewpoint Molecular Targeting Inc. | National Institutes of Health | $2.00 | 10/12/22 |
| BARDA to award Vir Biotech funding to advance the development of VIR-2482 and prophylactic antibodies for seasonal and pandemic influenza | Vir Biotechnology Inc. | Biomedical Advanced Research and Development Authority | $1,000.00 | 10/4/22 |
| NIDCR to award Virtici funding to develop VTC-886 for periodontal disease | Virtici LLC | National Institute of Dental and Craniofacial Research | Payment unspecified | 10/5/22 |
| National Heart, Lung, and Blood Institute to award Vivasc Therapeutics funding to use cardiac targeting peptide to deliver miRNAs to cardiomyocytes to reverse cardiac hypertrophy and heart failure | Vivasc Therapeutics Inc. | National Heart, Lung, and Blood Institute | $0.28 | 10/20/22 |
| Victorian Government to award WEHI funding to use Brain-POP clinical trial platform to test the effect of novel therapy against brain cancer | Walter and Eliza Hall Institute of Medical Research | Victorian State Government | $16.00 | 10/31/22 |
| MRRF to award WEHI funding for GLIMMER program to research on drug failure, deliver therapies and develop tumor monitoring for glioblastoma | Walter and Eliza Hall Institute of Medical Research | Medical Research Future Fund | $4.60 | 10/11/22 |
| NIAMS to award Weill Cornell Medicine funding to study on mechanisms to identify and develop biomarkers and therapies against SLE in children | Weill Cornell Medicine | National Institute of Arthritis and Musculoskeletal and Skin Diseases | $8.30 | 10/21/22 |
| NIGMS to award Weill Cornell Medicine funding to conduct study evaluating role of noncoding RNAs against diseases | Weill Cornell Medicine | National Institute of General Medical Sciences | $2.10 | 10/13/22 |
| ALA to award Weill Medical College funding to develop LRG1 targets for the treatment of COVID-19 infection | Weill Medical College of Cornell University | American Lung Association | Payment unspecified | 10/12/22 |
| Unicancer to award Agendia funding to de-escalate endocrine therapy in women with early breast cancer | Agendia Inc. | The Unicancer Group | Payment unspecified | 11/16/22 |
| European Commission to award Allero Therapeutics funding to develop treatment for celiac disease using specific oromucosal immunotherapy technology | Allero Therapeutics BV | European Commission | $2.60 | 11/28/22 |
| U.S. Department of Defense to award Appili Therapeutics funding for development of ATI-1701 to prevent infection with Francisella tularensis | Appili Therapeutics Inc. | U.S. Department of Defense | $14.00 | 11/14/22 |
| National Institute of Health to award Aptinyx funding to develop NYX-783 for the treatment of opioid use disorder | Aptinyx Inc. | National Institute of Health | $5.60 | 11/3/22 |
| NIAID to award Baruch S Blumberg Institute funding to develop antiviral drug for yellow fever | Baruch S Blumberg Institute | National Institute of Allergy and Infectious Diseases | $5.49 | 11/21/22 |
| Bill & Melinda Gates Foundation to award Bayer funding to discover non-hormonal contraceptive against female contraception | Bayer AG | Bill & Melinda Gates Foundation | $12.00 | 11/8/22 |
| NIAID to award Case Western Reserve University funding to evaluate SCY-247 against Candida auris infection | Case Western Reserve University | National Institute of Allergy and Infectious Diseases | $3.00 | 11/30/22 |
| US DoD to award Cerus funding for the development of Lyocryo to treat trauma induced bleeding | Cerus Corp. | U.S. Department of Defense | $9.10 | 11/2/22 |
| Invest Northern Ireland to award CV6 Therapeutics funding to develop CV6-168 for cancer | CV6 Therapeutics Ltd. | Invest Northern Ireland | $3.45 | 11/2/22 |
| Bill & Melinda Gates Foundation to award Cyclica funding for multi-targeted drug discovery program to advance non-hormonal contraceptive medicines | Cyclica Inc. | Bill & Melinda Gates Foundation | $1.80 | 11/15/22 |
| Leiden University Medical Center to award Cynata Therapeutics funding to investigate Cymerus MSCs as a treatment for renal graft rejection and to reduce the requirement for anti-rejection drugs | Cynata Therapeutics Ltd. | Leiden University Medical Center | Payment unspecified | 11/4/22 |
| DeGregorio Family Foundation to award Dana-Farber funding to develop CAR T immunotherapies for the treatment of gastroesophageal cancer | Dana-Farber Cancer Institute Inc. | DeGregorio Family Foundation | $0.25 | 11/1/22 |
| Bill & Melinda to award Daré funding to support Hydrogel gel formulation for the delivery of live biotherapeutics against vaginal infections | Daré Bioscience Inc. | Bill & Melinda Gates Foundation | $0.58 | 11/15/22 |
| DoD to award Emergent Biosolutions funding to conduct clinical study on CHIKV-VLP vaccine against chikungunya | Emergent Biosolutions Inc. | U.S. Department of Defense | $10.00 | 11/14/22 |
| FightMND to award Epicentrx funding to support the study of RRx-001 for motor neuron disease | Epicentrx Inc. | FightMND ABN | Payment unspecified | 11/29/22 |
| Pankind to award Garvan Institute funding to develop tailored therapy against pancreatic cancer | Garvan Institute of Medical Research | Pankind | $0.30 | 11/18/22 |
| NIH to award Harvard Medical School funding for phase II study of DBP against opioid use disorder | Harvard Medical School | National Institutes of Health | Payment unspecified | 11/23/22 |
| NCI to award Indee Labs funding to scale up and out the Hydropore for cell therapy | Indee Labs | National Cancer Institute | $2.00 | 11/2/22 |
| NSERC to award InMed Pharmaceuticals' funding to conduct research and development studies of cannabinoid pharmaceutical candidates, including INM-900 for neurodegenerative diseases | Inmed Pharmaceuticals Inc. | Natural Sciences and Engineering Research Council of Canada | Payment unspecified | 11/16/22 |
| JDRF to award Junta de Andalucía funding to develop BL-001 against type I diabetes | Junta De Andalucia | Juvenile Diabetes Research Foundation Ltd. | $0.79 | 11/29/22 |
| Swedish Research Council to award Karolinska Institutet researchers funding to support research in various indications including cardiovascular disease, tuberculosis, hyperinflammatory , leukemia, obesity and type 2 diabetes | Karolinska Institutet | Swedish Research Council | $8.47 | 11/11/22 |
| SRC to award KI researchers funding for the research projects in the fields of immune system, neurogeriatrics, lung cancer diagnostics, PD, CVD, dementia, kidney diseases and AD | Karolinska Institutet | Swedish Research Council | $3.37 | 11/8/22 |
| Swiss Bridge Foundation to award Karolinska Institutet funding to research about colorectal cancer | Karolinska Institutet | Swiss Bridge Foundation | $0.25 | 11/1/22 |
| National Cancer Institute to award Kinimmune funding to develop KIN-102 for solid tumor cancers | Kinimmune Inc. | National Cancer Institute | $0.40 | 11/9/22 |
| National Institute of Dental and Craniofacial Research to award Kovina Therapeutics funding to develop human papillomavirus E6 inhibitors for the treatment of cancers caused by the virus | Kovina Therapeutics Inc. | National Institute of Dental and Craniofacial Research | $0.27 | 11/2/22 |
| European Innovation Council to award Meletios Therapeutics funding to develop MLT-103 for SARS-CoV-2 infection | Meletios Therapeutics SAS | European Innovation Council | $2.50 | 11/3/22 |
| NIAID to award funding to Microbiotix to optimize broad-spectrum filovirus inhibitors against filovirus infection | Microbiotix Inc. | National Institute of Allergy and Infectious Diseases | $2.07 | 11/21/22 |
| National Cancer Institute to award Microvascular Therapeutics funding for a brain tumor program in combination with high-intensity focused ultrasound | Microvascular Therapeutics LLC | National Cancer Institute | Payment unspecified | 11/21/22 |
| Leo Foundation to award Monash BDI researcher funding to develop treatment for psoriasis | Monash Biomedicine Discovery Institute | LEO Pharma A/S | $0.84 | 11/9/22 |
| National Cancer Institute to award Mosaic Immunoengineering funding to develop MIE-101 for cancer | Mosaic Immunoengineering Inc. | National Cancer Institute | $4.30 | 11/1/22 |
| NIDA to award OHSU funding to develop SRI-42718 against chikungunya virus infection | Oregon Health Sciences University | National Institute of Allergy and Infectious Diseases | $4.70 | 11/21/22 |
| National Institute of Diabetes and Digestive and Kidney Diseases to award Orsobio funding to fund IND-enabling activities for TLC-1235 | Orsobio Inc. | National Institute of Diabetes and Digestive and Kidney Diseases | $2.30 | 11/2/22 |
| NIH to award Pharmajet funding to support a study comparing administration of human papillomavirus virus vaccine using Tropis intradermal needle-free injection system to traditional needle and syringe intramuscular administration | Pharmajet Inc. | National Institutes of Health | $0.80 | 11/29/22 |
| Raesedo received a grant for development of surfactant protein A-derived peptidomimetics against asthma | Raesedo Inc. | National Heart, Lung, and Blood Institute | $3.40 | 11/18/22 |
| GIRF to award Rarecyte funding to support clinical trial for evaluating CTC and biomarker analysis for gastrointestinal cancer | Rarecyte Inc. | Gastro-Intestinal Research Foundation | Payment unspecified | 11/3/22 |
| KDDF to award investment funding grant to develop SK Biopharmaceuticals' SKL-27969 against advanced solid tumors | SK Biopharmaceuticals Co. Ltd. | Korea Drug Development Fund | Payment unspecified | 11/13/22 |
| BMGF to award Touchlight funding to develop thermostable doggybone DNA vaccine platform | Touchlight Genetics Ltd | Bill & Melinda Gates Foundation | Payment unspecified | 11/29/22 |
| Foundation for Sarcoidosis Research to award University of Colorado School of Medicine funding to conduct sarcoidosis research and for identifying neurosarc biomarkers | University of Colorado School of Medicine | Foundation for Sarcoidosis Research | 0.02 | 11/23/22 |
| NCI to award University of Miami STTR grant for the phase I clinical study of immunotherapy against cancer including leukemia | University of Miami Miller School of Medicine | National Cancer Institute | $2.00 | 11/15/22 |
| DeGregorio FF to award UPenn funding to develop genetically engineered CAR implanted stem cell therapeutics for GEJ cancer | University of Pennsylvania | DeGregorio Family Foundation | $0.25 | 11/9/22 |
| PFF to award University of Pennsylvania funding to research on metabolic dysfunction and epigenetic reprogramming in distal alveolar epithelial progenitor cell function and idiopathic pulmonary fibrosis | University of Pennsylvania | Pulmonary Fibrosis Foundation | $0.10 | 11/1/22 |
| DOD to award UTMB funding to develop vaccine candidates, HDT-321 for hemorrhagic fever virus and HDT-331 for Nipah virus | University of Texas Medical Branch at Galveston | US Department of Health and Human Services | $87.40 | 11/30/22 |
| National Cancer Institute to award Vergent Bioscience funding to evaluate VGT-309 for intraoperative imaging of tumors in patients undergoing lung cancer surgery | Vergent Bioscience Inc. | National Cancer Institute | $2.00 | 11/30/22 |
| NINDS to award Washington University funding to study on genes and nerve cells to develop therapies against chronic pain | Washington University School of Medicine in St Louis | National Institute of Neurological Disorders and Stroke | $11.70 | 11/4/22 |
| NCI to award Weill Cornell Medicine funding to develop messenger RNA (mRNA) vaccines to deter cancer | Weill Cornell Medicine | National Cancer Institute | $5.70 | 11/12/22 |
| NIH to award Aptinyx funding to develop NYX-783 against opioid use disorder | Yale School of Medicine | National Institutes of Health | $5.60 | 11/3/22 |
| Innovate UK to award Alchemab Therapeutics funding to advance the development of a modifying therapy for Huntington's disease | Alchemab Therapeutics Ltd. | Innovate UK | $2.00 | 12/16/22 |
| California Institute for Regeneration Medicine to award Angiocrine Bioscience funding to develop AB-205 for lymphoma undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation | Angiocrine Bioscience Inc. | California Institute for Regeneration Medicine | $15.00 | 12/20/22 |
| Cystic Fibrosis Foundation to award Aridis Pharmaceuticals funding to develop AR-501 for controlling debilitating chronic lung infections in cystic fibrosis patients | Aridis Pharmaceuticals Inc. | Cystic Fibrosis Foundation | $4.85 | 12/12/22 |
| Bill & Melinda Gates Foundation to award Aspen Pharmacare funding to expand the supply and sourcing of affordable vaccines manufactured in Africa | Aspen Pharmacare Holdings Ltd. | Bill & Melinda Gates Foundation | $15.00 | 12/12/22 |
| US DoD to award Bavarian Nordic funding to develop MVA-BN WEV against Western, Eastern and Venezuelan equine encephalitis virus | Bavarian Nordic A/S | US Department of Defense | $83.00 | 12/23/22 |
| CIRM to award Calidi Biotherapeutics funding to advance SuperNova-1 program against solid tumor | Calidi Biotherapeutics Inc. | California Institute of Regenerative Medicine | $3.10 | 12/13/22 |
| New South Wales Health to award Centenary Institute funding to support the development of a nasally inhaled COVID-19 vaccine | Centenary Institute Cancer Medicine & Cell Biology | New South Wales Government Health | $1.00 | 12/22/22 |
| CIRM to award COH funding to support the manufacturing of NNV-2 for phase I study in glioma patients | City of Hope | California Institute of Regenerative Medicine | $12.00 | 12/13/22 |
| Prostate Cancer Foundation to award City of Hope funding to develop CAR T cell therapies against advanced prostate cancer | City of Hope | Prostate Cancer Foundation | $8.00 | 12/7/22 |
| NEA to award Emory University funding to support research on botanical-derived small molecules against atopic dermatitis | Emory University | National Eczema Association | Payment unspecified | 12/6/22 |
| Bill & Melinda to award Explorna funding to develop mRNA technology for the production of vaccines and monoclonal antibodies | Explorna Therapeutics Sp. z.o.o. | Bill & Melinda Gates Foundation | $0.81 | 12/8/22 |
| UK National Health Service to award Genomics England funding for genomics research against cancer and genetic diseases | Genomics England Ltd. | UK National Health Service | $127.31 | 12/22/22 |
| EIC to award Herantis Pharma funding to develop HER-096 against Parkinson’s disease | Herantis Pharma plc | European Commission | $2.65 | 12/19/22 |
| DoD to award INmune Bio funding to support a research study for XPro-1595 against TBI in the development of Alzheimer’s disease | Inmune Bio Inc. | US Department of Defense | Payment unspecified | 12/22/22 |
| European Investment Council to award Ionctura funding to develop IOA-289 for pancreatic cancer | Ionctura BV | European Investment Council | $2.65 | 12/20/22 |
| Lung Cancer Research to award Massachusetts General Hospital funding to conduct research on ALK-positive related lung cancer project to develop ALK-positive targeted therapies | Massachusetts General Hospital | Lung Cancer Research Foundation | $0.25 | 12/22/22 |
| Lung Cancer Research Foundation to award Memorial Sloan-Kettering Cancer Center funding to conduct research on epigenomic mechanisms of ALK TKI resistance to develop ALK-positive targeted therapies | Memorial Sloan Kettering Cancer Center | Lung Cancer Research Foundation | $0.25 | 12/22/22 |
| NHMRC to award BDI funding to 16 research projects to identify targets and to improve therapeutic strategies against various diseases | Monash Biomedicine Discovery Institute | National Health and Medical Research Council | $16.00 | 12/15/22 |
| NHMRC to award Murdoch Children’s Research Institute’s funding to advance earlier diagnosis and treatments for childhood conditions | Murdoch Childrens Research Institute | National Health and Medical Research Council | $6.00 | 12/15/22 |
| Horizon Europe to award OmniSpirant funding for INSPIRE initiative to develop gene therapy treatment for lung cancer | Omnispirant Ltd. | The European Union | $13.47 | 12/6/22 |
| European Union awarded ORYZON grant to further explore the role of iadademstat in oncological immunotherapy approaches including solid tumors | Oryzon Genomics SA | The European Union | $0.42 | 12/16/22 |
| UMDF to award Primera funding to study on therapies against mitochondrial diseases | Primera Therapeutics Inc. | United Mitochondrial Disease Foundation | Payment unspecified | 12/29/22 |
| Bill & Melinda to award Rigimmune funding to advance the development of SLR platform for respiratory diseases and influenza | Rigimmune Inc. | Bill & Melinda Gates Foundation | Payment unspecified | 12/7/22 |
| NIH to award Scynexis funding to study SCY-247 to treat Candida auris infections | Scynexis Inc. | National Institutes of Health | $3.00 | 12/1/22 |
| NCI to award Sellas Life Sciences funding to evaluate GFH-009 against pediatric solid tumors and leukemia | Sellas Life Sciences | National Cancer Institute | Payment unspecified | 12/6/22 |
| NCI to award Senhwa Biosciences funding to develop CX-5461 for cancer | Senhwa Biosciences Inc. | National Cancer Institute | Payment unspecified | 12/1/22 |
| French government to award Spikimm funding to develop SPK-001 for COVID-19 | Spikimm SAS | French government | $15.80 | 12/8/22 |
| NEA to award University of British Columbia funding to study the role of inhibition of tissue resident memory T-cells as a therapy for contact hypersensitivity | University of British Columbia | National Eczema Association | Payment unspecified | 12/6/22 |
| NIH to award UMMSM funding to study the genetic cause of IBD in hispanic patients | University of Miami Miller School of Medicine | National Institutes of Health | $2.90 | 12/19/22 |
| Bill & Melinda Gates Foundation to award Vaxart funding to study on vaccine against norovirus infection in breastfeeding mothers and infants | Vaxart Inc. | Bill & Melinda Gates Foundation | Payment unspecified | 12/1/22 |
| NHLBI to award Weill Cornell Medicine funding to support clinical study for doxycycline against emphysema associated HIV | Weill Cornell Medicine | National Heart Lung and Blood Institute | $7.80 | 12/13/22 |
| NEA to award Women's College Hospital funding to study the long-term safety of topical corticosteroids in treatment of atopic dermatitis | Women's College Hospital | National Eczema Association | Payment unspecified | 12/6/22 |